-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2424 Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Program: Oral and Poster Abstracts
Session: 908. Outcomes Research: Myeloid Malignancies: Poster I
Hematology Disease Topics & Pathways:
Research, AML, Acute Myeloid Malignancies, Clinical Research, Diseases, Real-world evidence, Registries, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Hervé Dombret, MD, PhD1, Alexandra Coelho2*, Laurène Fenwarth, MD, MSc3*, Jean-Baptiste Micol, MD4, Lionel Ades, MD, PhD5,6, Thomas Cluzeau, MD, PhD7, Emmanuel Raffoux, MD8*, Sylvain Chantepie, MD9*, Pierre Arnautou, MD10*, Mathieu Leclerc, MD, PhD11*, Delphine Lebon, MD12*, Thorsten Braun, MD, PhD13, Ollivier Legrand, MD14*, Claire Bories, MD15*, Céline Berthon, MD16*, Juliette Lambert, MD, PhD17*, Ahmad Aljijakli, MD18*, Emilie Lemasle, MD19*, Pascal Turlure, MD20*, Benjamin Carpentier, MD21*, Jamile Frayfer, MD22*, Stephanie Haiat, MD23*, Ambroise Marcais, MD, PhD24*, Isabelle Plantier, MD25*, Kevin-James Wattebled, MD26*, Madalina Uzunov, MD27*, Iona Vaida, MD28*, Mael Heiblig29*, Lauris Gastaud, MD30*, Laure Farnault, MD31*, Dominique Penther, MD32*, Nicole Raus, RN33*, Renaud Buffet, MD34*, Karine Celli-Lebras, RN35*, Claude Preudhomme, PharmD, PhD36*, Nicolas Duployez, PharmD, PhD37*, Raphael Itzykson38 and Stephane De Botton39*

1Department of Clinical Hematology, Saint Louis University Hospital, Université Paris Cité-AP-HP, Paris, France
2ALFA Project Manager, Paris, France
3Hematology Laboratory, CHU Lille, Lille, France
4Hematology Department, Gustave Roussy Institute, Villejuif, France
5Hématologie clinique, Hôpital Saint-Louis, Paris, France
6Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
7Department for Clinical Hematology, Nice University Hospital, Nice, Provence Alpes Cote d'Azur, France
8Hematology Department, Saint Louis Hospital, Paris, France
9Basse-Normandie Institute of Hematology, CHU de Caen, Caen, France
10HIA Percy, Clamart, FRA
11Hematology Department, Henri Mondor University Hospital, AP-HP, Créteil, France
12Hematology Department, CHU Amiens, Amiens, France
13Clinical Hematology, Avicenne University Hospital, Assistance Publique – Hôpitaux de Paris, Bobigny, France
14Clinical Hematology and Cellular Therapy Department, Sorbonne University, Saint Antoine Hospital, INSERM UMRs U938, Paris, France
15Service d'Hématologie, CH de Lens, Lens, FRA
16Hematology Department, CHRU Lille, Lille, France
17Clinical Hematology Department, Versailles Hospital, Le Chesnay-Rocquencourt, France
18CH Argenteuil, Argenteuil, France
19Hematology Department, Centre Henri Becquerel, Rouen, France
20Service d'Hématologie Clinique, CHU de Limoges, Limoges, France
21Saint Vincent de Paul Hospital, Lille, FRA
22Hospital Saint Faron, Meaux, FRA
23Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
24Hopital Necker, Paris, France
25Hopital Victor Provo, Roubaix, France
26CH Dunkerque, Dunkerque, FRA
27Clinical Hematology Department, Pitié-Salpétrière University Hospital, AP-HP, Paris, France
28Centre Hositalier de Pontoise, Pontoise, FRA
29Centre Hospitalier Lyon Sud, Centre Hospitalier Lyon Sud, Service Hématologie, Centre d’Investigation des thérapeutiques en oncologie et hématologie de Lyon (CITHOL), Vourles, Rhône Alpes, France
30Centre Antoine Lacassagne, Nice, France
31APHM Hopital La Conception, Marseille, FRA
32Department of Genetic Oncology, Henri Becquerel Center, CHU Rouen, Rouen, France
33SFGM-TC coordination, Hôpital Lyon Sud, Lyon, FRA
34ALFA coordination, Hôpital Saint-Louis, Paris, FRA
35ALFA Coordination, Hôpital Saint-Louis, Paris, France
36Laboratory of Hematology-Molecular Biology, CHU Lille, Lille, France
37Laboratory of Hematology-Molecular Biology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
38Université de Paris, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France, Paris, France
39Institut Gustave Roussy, Villejuif, France

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients.

Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractory) prospective observational study (ALFA-PPP, NCT04777916) aiming to collect clinical data and bio-samples in all AML patients aged ≥18y referred to 27 ALFA centers. Data/sample collection was structured by approved therapies including best supportive care (BSC). Patients treated on a compassionate basis or included in a clinical trial are also registered. Treatment decision-making criteria are prospectively collected. All patients should have a centralized genomic diagnosis (50-gene NGS panel) and molecular/flow MRD follow-up. We report here the initial observations made in the first 648 patients included between April 2022 and September 2023 in the newly diagnosed cohort. The current patient recruitment rate is around 650 new patients per year.

Results. There were 340 males and 308 females (median age, 65y [range, 18-100]; ECOG-PS 0/1/2/3/4/NA, 195/295/97/33/8/19; HCT-CI comorbidity index 0/1/2/3+/NA, 54/269/106/216/3; median WBC, 6.9 G/L [IQR, 2.4-26]; median marrow blast percentage, 53% [IQR, 29-79]). The numbers of patients with de novo, post-MDS, post-MPN and therapy-related AML (tAML) were 467 (72%), 54 (8%), 58 (9%) and 69 (11%), respectively. ELN-2022 risk was favorable in 136 (21%), intermediate in 129 (20%), adverse in 340 (52.5%), and not available in 43 (6.5%) patients. In the 595 patients tested, incidences of NPM1, FLT3-ITD, IDH1/2, TP53 and secondary AML (sAML)-like gene mutations were 27%, 19%, 22%, 12% and 48%, respectively.

A minority of 172 (26.5%) patients were included into a clinical trial frontline (investigator/company-sponsored trial, 140/32 patients; intensive/less intensive/two-option trial, 142/20/10 patients). They were significantly younger than the 476 (73.5%) patients treated outside any clinical trial (median age, 55 vs 69y, p<.001). In these 476 patients, treatment decision was intensive in 266 (median age, 62y [18-79]; 210 7+3 ± GO or midostaurin, 54 CPX-351, 2 others), less intensive in 185 (median age, 76y [36-100]; 149 AZA-VEN, 18 AZA or low-dose cytarabine alone, 13 AZA-ivosidenib, 5 others), and BSC in 21 patients, while the 4 remaining patients early died before any treatment decision.

By investigator declaration, the main reason for selecting a less intensive treatment was advanced age (n=138), AML characteristics/risk (n=19), concomitant diseases (n=16), patient’s choice (n=1), or other (n=11), with good statistical correlations with objective data. The objective factors independently associated with the choice of a less intensive option were age ≥65y (p<.001), higher ECOG-PS (p<.001) or comorbidity index (p=.001), but also post-MDS (p=.001) or post-MPN (p<.001) AML, lower WBC (p=.022), poor cytogenetics (p=0.046), and TP53 (p=.003) or IDH1/2 (p=.003) mutation.

A total of 89/476 (18.5%) patients received an allogeneic SCT during the first 6 months of follow-up, including 81 intensively and only 8 less-intensively treated patients. In the 185 less-intensively treated patients with a median follow-up of 15 months, median overall survival (OS) was 10.3 months (95% CI, 7.2-12.9) with a 12-month estimate at 45.3% (95% CI, 37.7-52.5). In these patients, multivariate stepwise Cox model evidenced higher ECOG-PS (p=.038), concomitant diseases (p=.003), tAML (p=.046), higher marrow blast percentage (p=.024), sAML-like (p=.048) and TP53 (p<.001) mutation as bad-prognosis factors for OS, while IDH1/2 mutations (p=.001) were associated with longer OS.

Conclusions.

Awaiting the ELN-2024 recommendations for less-intensive AML therapies, this prospective real-life study confirms their rising place in a European context. Rather than age by itself, survival after less-intensive treatment is governed by multiple independent clinical and genomic factors. Future reports will update these observations on an annual basis.

Disclosures: Dombret: Jazz Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; BMS-Celgene: Research Funding; Daiich Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Astellas: Research Funding. Micol: Gilead Sciences: Honoraria; AbbVie: Honoraria; SERVIER: Honoraria; Astellas Pharma: Honoraria; Jazz Pharmaceuticals: Honoraria. Ades: Abbvie: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Cluzeau: BMS: Consultancy, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Servier: Consultancy, Speakers Bureau; Jazz Pharma: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Amgen: Speakers Bureau; Takeda: Speakers Bureau; Keros: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Speakers Bureau; Syros: Speakers Bureau; Pfizer: Other: International Congress. Braun: BMS: Consultancy, Honoraria. Heiblig: Jazz pharmaceutical: Honoraria; Abbvie: Honoraria; Pfizer: Honoraria; Servier: Honoraria; Astellas: Honoraria. Buffet: Pfizer: Research Funding; Astellas: Research Funding; Servier: Honoraria, Research Funding; BMS-Celgene: Research Funding; Jazz Pharma: Research Funding; Da Voltera: Ended employment in the past 24 months. Preudhomme: servier: Honoraria; jazz: Honoraria; astellas: Honoraria; abbvie: Other: travel cost and ash registration. Itzykson: Abbvie: Research Funding; Advesya: Research Funding.

*signifies non-member of ASH